Advances in Bioresearch
Adv. Biores., Vol 15 (2) March 2024: 148-154

Print ISSN 0976-4585; Online ISSN 2277-1573
Journal's URL:http://www.soeagra.com/abr.html
CODEN: ABRDC3
DOI: 10.15515/abr.0976-4585.15.2.148154

Advances in Bioresearch

REVIEW ARTICLE

Precision Medicine in Chronic Kidney Disease: Personalized Approaches to Treatment

[1]Iype Cherian, [2]Harisinh Parmar, [3]Bammidi Rohit Kumar, **[4]Abhijit Nashte, [5]Aparna Patange**
Dept. of Neurology, Krishna Vishwa Vidyapeeth, Karad, Maharashtra, India
3-5Department of Medicine, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth, Karad, Maharashtra (Correspondence)

,

ABSTRACT

The significant global health burden of chronic kidney disease (CKD) has led to a move towards precision medicine for individualised therapies. This study examines how personalised methods to CKD management are developing, with a focus on how biomarkers, genetic analysis, and cutting-edge therapies are integrated. Biomarkers, which include urine and serum indicators including NGAL, KIM-1, and UACR, are essential instruments for the early identification, prognosis, and therapy grouping of individuals with chronic kidney disease. Personalised medicines are made possible by genetic profiling, which uses genome-wide association studies to uncover complex illness susceptibilities and assist in selecting therapeutic targets. New insights into the aetiology of chronic kidney disease (CKD) can be gained through emerging technologies, such as AI-driven analytics and sophisticated imaging modalities, which can aid in predictive modelling for better treatment approaches. In order to effectively manage chronic kidney disease (CKD), lifestyle changes—such as customised food programmes, exercise routines, and patient education—are essential. Validating biomarkers, protecting data privacy, and maximising cost-effective adoption continue to present difficulties. However, with to developments in omics technology, AI integration, and tailored treatments, the future of precision medicine in CKD is bright. By incorporating these diverse methods into standard treatment, CKD management may be completely transformed, opening the door to better patient outcomes and individualised therapies.

Keywords: *Chronic kidney disease, Precision medicine, Biomarkers, Genetic profiling, Personalized therapies*

Received 24.11.2023 Revised 01.12.2023 Accepted 21.02.2024

How to cite this article:
Iype Cherian, Harisinh Parmar, Bammidi Rohit Kumar, Abhijit N, Aparna P. Precision Medicine in Chronic Kidney Disease: Personalized Approaches to Treatment. Adv. Biores., Vol 15 (2) March 2024:148-154

INTRODUCTION

Millions of people worldwide are impacted by chronic kidney disease (CKD), which also places a heavy financial strain on healthcare systems throughout the globe [1]. The conventional paradigm for managing chronic kidney disease (CKD) has mostly been one-size-fits-all, which frequently leads to less-than-ideal results and differences in treatment responses across afflicted parties [2].

Precision medicine has changed medical paradigms in the last several years in many different disciplines. Its goal is to personalise patient care by taking lifestyle, environmental, and genetic aspects into account [3]. Precision medicine's core competency is its ability to analyse the variability within disease entities and customise therapies to each patient's unique requirements and features [4].

The field of chronic kidney disease (CKD) care has seen a resurgence of optimism with the use of precision medicine ideas in nephrology. Chronic kidney disease (CKD) is a complex illness with a range of aetiologies, each with unique pathophysiological processes and clinical patterns [5]. Because of its intrinsic complexity, diagnosis and treatment can be difficult, and a transition from a generalised therapeutic approach to one that recognises and accommodates individual variances is required [6].

Personalised risk stratification techniques, molecular profiling, and cutting-edge technology are all integral to the notion of precision medicine in chronic kidney disease [7]. In this paradigm, biomarkers are essential because they function as markers of the course of the disease, help with early identification, and provide precise prognostication [8]. Novel urine and serum biomarkers, such as kidney injury molecule-1 (KIM-1), urinary albumin-to-creatinine ratio (UACR), and neutrophil gelatinase-associated

lipocalin (NGAL) are a few examples of novel biomarkers that have emerged as promising tools for assessing kidney injury and forecasting unfavourable outcomes in chronic kidney disease (CKD) [9].

Furthermore, the development of high-throughput omics technologies—such as transcriptomics, proteomics, metabolomics, and genomics—has made it possible to fully comprehend the molecular foundations of chronic kidney disease (CKD) [10]. By providing previously unheard-of insights into the complex interactions between genetic susceptibilities and environmental variables, these technologies are opening the door to more accurate risk assessment and individualised treatment plans for individuals with chronic kidney disease [11].

Precision medicine holds great potential, but integrating it into standard clinical practice is fraught with difficulties. Validation and standardisation of selected biomarkers and molecular targets are among the main challenges [12]. Even though a large number of possible biomarkers have been found, research and validation studies are still being conducted to determine their clinical value and repeatability across a variety of patient groups [13].

Moreover, a collaborative strategy including cooperation between nephrologists, geneticists, bioinformaticians, and other allied healthcare workers is required for the use of precision medicine in CKD [14]. Other challenges include integrating different datasets, translating research findings into practical treatment procedures, and ethically addressing patient data privacy [15].

The potential of precision medicine in CKD is evident, notwithstanding these obstacles. Individualised treatment plans have the power to slow the course of a disease, lower unfavourable occurrences, and improve results [16]. Furthermore, a new era in the treatment of CKD is heralded by the introduction of cutting-edge therapeutic techniques such gene-based treatments and precision-targeted pharmaceuticals [17].

In summary, the application of precision medicine concepts to chronic kidney disease (CKD) signifies a paradigm change in nephrology by providing tailored strategies that may lead to better patient outcomes. The purpose of this review is to examine and clarify the rapidly changing field of precision medicine in CKD, including its advantages, disadvantages, and potential future paths.

THE PERSONALISED DIAGNOSIS AND BIOMARKERS

When it comes to chronic kidney disease (CKD), precision medicine highlights the crucial role that biomarkers play in transforming diagnostic techniques and enabling individualised patient treatment methods [1]. Biomarkers are quantifiable signs that represent the existence, intensity, or course of a disease. They can be any kind of chemicals, genes, proteins, or biological processes [2]. Biomarkers are essential for the early identification, precise diagnosis, risk assessment, and prognosis of CKD, which helps to customise treatment approaches [3].

Numerous interesting candidates for CKD evaluation have been identified and validated as a result of advances in biomarker research. These biomarkers are associated with several areas, such as inflammation, fibrosis, renal damage, and metabolic changes [4]. Urinary biomarkers have been the subject of much research because of their non-invasive nature and capacity to provide light on renal disease [5].

Notably, an early biomarker for acute kidney injury (AKI) detection and CKD disease severity assessment has been identified: neutrophil gelatinase-associated lipocalin (NGAL), a protein produced during kidney damage [6]. NGAL levels are significantly higher in serum and urine during episodes of renal damage, providing physicians with a useful tool for prognostication and prompt management [7].

Similarly, as a biomarker for proximal tubular damage in chronic kidney disease (CKD), kidney injury molecule-1 (KIM-1) has attracted a lot of attention [8]. Research has indicated that it can be useful in differentiating between CKD aetiologies and forecasting the course of the illness, which helps with risk assessment and customised therapy planning [9].

A key component of diagnosing and tracking chronic kidney disease (CKD) is the urine albumin-to-creatinine ratio (UACR), a traditional biomarker for albuminuria [10]. Increased cardiovascular risk and glomerular damage are indicated by elevated levels of UACR, highlighting the importance of this marker not only for renal evaluation but also for predicting unfavourable outcomes related to chronic kidney disease [11].

Novel serum indicators have become useful tools in the precise diagnosis of chronic kidney disease (CKD), in addition to urine diagnostics. A hormone that mainly controls the metabolism of phosphate and vitamin D, fibroblast growth factor 23 (FGF-23), has drawn notice for its potential as a prognostic indicator in CKD-mineral and bone disease (CKD-MBD) [12]. In patients with chronic kidney disease (CKD), elevated levels of FGF-23 are associated with worse cardiovascular outcomes and disease progression. This suggests that FGF-23 may be a useful target for treatment of anomalies related to mineral metabolism [13].

The range of possible biomarkers in CKD has also increased with the incorporation of high-throughput omics technologies, including as metabolomics and genomics [14]. Personalised risk assessment and tailored therapies have been made possible by the identification of genetic variations linked to CKD susceptibility and progression by genome-wide association studies (GWAS) [15].

Clarifying the small-molecule metabolites found in biological samples using metabolic profiling provides information on altered metabolic pathways in chronic kidney disease (CKD) [16]. These metabolic patterns have the potential to uncover new biomarkers that might support CKD subtype categorization, treatment response monitoring, and early diagnosis [17].

Nevertheless, there are still issues with the clinical translation and standardisation of the many discovered biomarkers. In order to guarantee the repeatability and dependability of biomarker usefulness, validation research including a variety of CKD populations is important [18]. Furthermore, research and optimisation on the incorporation of several biomarkers into a coherent diagnostic algorithm are still underway [19].

To sum up, biomarkers represent a revolutionary advancement in precision medicine for chronic kidney disease (CKD), providing a customised approach to risk assessment and diagnosis. Their incorporation into clinical practice has great potential to direct individualised treatment plans and enhance CKD patient outcomes.

GENETIC TESTING AND TAILORED TREATMENT

In order to understand the complex genetic foundations of chronic kidney disease (CKD) and develop tailored therapeutic treatments and patient care, the integration of genetic profiling offers great potential [1]. Because of the wide range of genetic variables that impact the illness's susceptibility, development, and response to therapy, chronic kidney disease (CKD) displays significant heterogeneity [2].

Finding genetic variations linked to CKD susceptibility and progression has been made possible thanks in large part to genome-wide association studies (GWAS) [3]. The pathophysiology of CKD subtypes has been linked to variations in genes encoding proteins involved in renal function, inflammation, fibrosis, and electrolyte balance [4]. For example, a higher risk of chronic kidney disease (CKD) and worse outcomes have been associated with polymorphisms in genes encoding components of the renin-angiotensin-aldosterone system (RAAS) [5].

Clinicians can identify patients at increased risk of complications or disease progression by using an understanding of the genetic landscape of chronic kidney disease (CKD) to help with risk stratification and prognostication [6]. Genetic profiling also makes it easier to identify possible therapeutic targets, which paves the way for the creation of precision-targeted treatments that are customised to a patient's unique genetic susceptibilities [7].

Within the field of precision medicine, pharmacogenomics aims to clarify the ways in which a person's genetic composition affects their reaction to medication [8]. Pharmacogenomic investigations in the setting of CKD have brought to light differences in drug-metabolizing enzymes and drug transporters that affect the safety and effectiveness of drugs often used in CKD care [9].

Pharmacokinetics and pharmacodynamics of various medications used in chronic kidney disease (CKD) are influenced by genetic polymorphisms that affect drug metabolism enzymes, such as cytochrome P450 enzymes, and transporters, such as organic cation transporters (OCTs) and multidrug resistance-associated proteins (MRPs) [10].

Customising medication schedules according to a person's genetic profile has the potential to maximise therapeutic benefit and reduce side effects [11]. Genetically-guided medication selection and personalised dosage regimens may enhance treatment results and reduce drug-related problems in patients with chronic kidney disease [12].

The development of precision medicine has also prompted research into cutting-edge treatment approaches that focus on certain genetic pathways linked to the aetiology of chronic kidney disease [13]. Gene-based treatments, such as CRISPR-Cas9 gene editing methods, have the potential to fix genetic flaws that underlie hereditary types of chronic kidney disease [14]. Though still in its infancy, the field of precision medicine may benefit from targeted genetic therapies in the future, since they may be able to stop or even reverse the course of illness in individuals with chronic kidney disease (CKD) who carry particular genetic abnormalities [15].

Nevertheless, there are obstacles in the way of applying genetic findings to therapeutic practice. It will take a lot of work and cooperation to validate the clinical value of found genetic variations and provide strong guidelines for incorporating them into standard treatment [16]. Furthermore, ethical questions about patient privacy, genetic testing, and fair access to genetic treatments continue to be important [17].

To sum up, genetic profiling is essential to the CKD precision medicine era since it provides information about the disease's processes and opens the door to customised treatment approaches. Clinical decision-

making that incorporates genetic information has the potential to improve treatment effectiveness and patient outcomes for individuals with chronic kidney disease.

PRECISION MEDICINES AND EMERGING TECHNOLOGIES

Technology has played a major role in the development of precision medicine in chronic kidney disease (CKD), ushering in a new age of cutting-edge therapeutic and diagnostic approaches [1]. These cutting-edge technologies attempt to enhance patient outcomes and customise CKD care using a range of strategies, including tailored medicines and advanced imaging methods [2].

Technologies for Imaging:

Modern imaging techniques have transformed renal imaging and made it possible to precisely characterise the structural and functional changes in chronic kidney disease (CKD) [3]. Examples of these techniques include computed tomography (CT), magnetic resonance imaging (MRI), and contrast-enhanced ultrasound. These imaging modalities help in early identification, disease staging, and therapy monitoring by providing insights into renal shape, vascular alterations, and perfusion abnormalities [4].

Advanced imaging modalities, such as arterial spin labelling and diffusion-weighted MRI, offer non-invasive evaluations of the perfusion dynamics and microstructure of renal tissue, enabling the early detection of renal failure and directing therapeutic treatments [5]. Furthermore, tailored therapeutics and personalised disease monitoring may be possible using molecular imaging methods that target certain biomarkers or molecular pathways involved in the pathophysiology of chronic kidney disease [6].

Both machine learning and artificial intelligence (AI):

In order to use enormous datasets, such as genetic profiles, imaging tests, and clinical data, to create prediction models and therapy algorithms for chronic kidney disease (CKD), the combination of AI and machine learning algorithms has shown to be a potent tool [7]. AI-driven predictive analytics help with illness progression prediction, risk assessment, and finding the best treatment plans based on the unique characteristics of each patient [8].

In order to provide prompt treatments to delay or prevent the course of chronic kidney disease (CKD), machine learning algorithms analyse complicated data patterns. This allows for the early identification of small changes in disease trajectories [9]. Furthermore, by combining information from many sources and offering tailored therapy suggestions, AI-driven decision support systems help physicians make therapeutic decisions [10].

Accurate Therapeutics:

Targeted therapies, which target certain molecular pathways implicated in the aetiology of chronic kidney disease, have been developed as a result of the precision medicine paradigm [11]. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), two therapeutic interventions that target the renin-angiotensin-aldosterone system (RAAS) and have been shown to have renoprotective effects by modifying hemodynamics and lowering proteinuria [12].

Thorough investigation is being done on novel medicines that target fibrotic pathways, inflammatory cascades, and metabolic abnormalities linked to chronic kidney disease (CKD) [13]. To mitigate inflammation-driven kidney damage, for example, anti-inflammatory drugs such as interleukin-1 and tumour necrosis factor-alpha inhibitors seem promising [14]. In a similar vein, drugs that target profibrotic signalling pathways, including TGF-β inhibitors, may be able to reduce renal fibrosis while maintaining renal function [15].

Additionally, new treatment techniques that minimise off-target effects and improve medication efficacy include nanomedicine and RNA-based therapeutics, which provide tailored delivery of therapeutic molecules [16]. Targeting certain genes linked to the advancement of CKD with RNA interference (RNAi) treatments shows promise in modifying disease pathways at the molecular level [17]. Systems for delivering drugs based on nanoparticles allow for precise drug targeting to renal tissues, improving therapeutic concentrations and lowering systemic toxicity [18].

However, strong validation through rigorous clinical studies and real-world applications is necessary before new technologies and precision medicines may be incorporated into standard clinical practice [19]. Furthermore, for these creative techniques to be widely adopted, factors like accessibility, scalability, and cost-effectiveness are still crucial [20].

In conclusion, a new era in the management of chronic kidney disease (CKD) is being ushered in by the combination of precision therapies and emerging technologies, which offer specialised diagnostic tools and focused interventions with the potential to improve patient outcomes.

ADJUSTMENTS TO LIFESTYLE AND TAILORED INTERVENTIONS

Precision medicine is a comprehensive approach to treating chronic kidney disease (CKD) that goes beyond pharmaceutical therapies. It emphasises the critical role that lifestyle changes and tailored interventions play in controlling the course of CKD and enhancing outcomes [1].

Nutritional Interventions:

In order to slow the development and consequences of CKD, nutritional measures are essential [2]. Individualised dietary guidelines, depending on the profiles of each patient, include changes to the macronutrient composition, limitations on the amount of sodium and phosphorus consumed, and adjustments to the amount of protein consumed in relation to renal function and proteinuria levels [3].

Customised meal plans take into account variables such comorbidities, nutritional status, and particular dietary needs depending on the stage of chronic kidney disease (CKD), with the goal of maximising metabolic parameters and minimising the strain on renal function [4]. For example, dietary therapies that aim to balance the acid-base by alkali supplements or dietary adjustments assist reduce metabolic acidosis, which is a prevalent CKD consequence that may delay the course of the illness [5].

Exercise and Physical Activity:

Personalised exercise plans and physical activity recommendations are essential to the management of chronic kidney disease (CKD) and have several advantages, such as better blood pressure control, cardiovascular health, and general well-being [6]. To guarantee safety and efficacy, however, individualised exercise prescriptions in CKD must take into account each patient's capacities, comorbidities, and stage of the disease [7].

A variety of activities, such as resistance training, flexibility training, and aerobic exercises, are included in tailored exercise programmes. These programmes are intended to meet certain objectives, such as enhancing cardiovascular fitness, muscular strength, and total functional capability [8]. Personalised exercise regimens often incorporate ways to overcome obstacles to physical activity, such as joint discomfort, weariness, or muscular weakness [9].

Giving Up Smoking and Making Lifestyle Changes:

Modifiable risk factors, such smoking, must be addressed in order to effectively manage chronic kidney disease (CKD). This highlights the significance of individualised therapies targeted at quitting smoking and changing one's lifestyle [10]. Behavioural support, medication, and treating underlying smoking reasons are all components of customised smoking cessation therapies [11].

Moreover, tailored lifestyle adjustments, such as methods for managing stress, improving sleep, and controlling weight, support the treatment of chronic kidney disease [12]. Lifestyle treatments that emphasise reducing stress through cognitive-behavioral therapy or mindfulness-based practices help manage psychological stresses, which may have an effect on the course of a disease and quality of life [13].

Patient Empowerment and Education:

Optimising care for patients with chronic kidney disease (CKD) requires providing them with individualised education and self-management techniques [14]. Better adherence to treatment regimens and lifestyle adjustments is made possible by individualised teaching programmes that are catered to each patient's unique qualities, such as health literacy, cultural views, and socioeconomic variables [15].

These courses cover everything from the genesis and course of CKD to medication adherence, dietary changes, and the significance of routine monitoring and follow-ups [16]. Furthermore, individualised self-management technologies, such online portals or mobile apps, promote patient involvement by letting people keep track of symptoms, keep an eye on important metrics, and access learning materials that are catered to their specific requirements [17].

Personalised lifestyle adjustments and treatments in the management of chronic kidney disease, however, need a multimodal strategy that includes patient participation, healthcare provider education, and the incorporation of personalised care plans into standard clinical practice [18]. The effective implementation of tailored therapies in the treatment of chronic kidney disease (CKD) depends on overcoming obstacles such scarce resources, patient adherence, and access to specialised care [19,20].

In summary, customised lifestyle therapies and changes are essential to precision medicine in chronic kidney disease (CKD), highlighting the role of individualised exercise programmes, nutrition planning, quitting smoking, and patient education in maximising patient outcomes.

Obstacles and Prospects for the Future

Precision medicine has the potential to completely transform the way chronic kidney disease (CKD) is managed, but a number of obstacles prevent it from being widely used, which calls for coordinated efforts to determine the path this science will take going forward [1].

Combining Diverse Data:

To provide a thorough picture of each person's unique CKD trajectory, one of the main problems is combining multiple datasets that include genetic information, biomarker profiles, clinical data, and lifestyle variables [2]. These datasets' complexity makes it difficult to harmonise, understand, and

exchange data; hence, creative ways to combine and analyse different data sources and sophisticated analytics are required [3].

Standardisation and Validation of Biomarkers:

Though comprehensive validation and standardisation across varied groups are still important, the development of biomarkers offers promise for personalised CKD therapy [4]. Clinical translation of established biomarkers is hampered by interlaboratory inconsistencies, variability in test techniques, and the requirement for longitudinal investigations to determine the prognostic and predictive utility of these biomarkers [5].

Regulatory and Ethical Considerations:

When implementing precision medicine in CKD, ethical issues pertaining to patient data privacy, informed permission for genetic testing, and fair access to newly developed precision medicines are crucial [6]. Important ethical issues include protecting patients from potential prejudice based on genetic information, maintaining patient autonomy, and maintaining confidentiality [7].

Budget-Friendliness and Availability:

Precision medicine treatments provide substantial obstacles in terms of accessibility and affordability, particularly in light of the high costs of genetic testing, improved imaging modalities, and personalised therapies [8]. It is still difficult to ensure cost-effectiveness while ensuring fair access to these technologies, therefore cutting costs through technology improvements and changes in health policy is necessary [9].

Multidisciplinary Cooperation and Instruction:

Collaboration amongst several disciplines, such as nephrologists, geneticists, bioinformaticians, data scientists, and allied healthcare professionals, is essential for the successful use of precision medicine in chronic kidney disease (CKD) [10]. The effective incorporation of precision techniques into therapy for patients with chronic kidney disease (CKD) requires promoting multidisciplinary education, encouraging joint research projects, and improving communication among experts [11].

Prospective Courses:

The future of precision medicine in chronic kidney disease (CKD) seems bright despite these obstacles, with many opportunities for development and innovation [12]. Progression in omics technologies, such as transcriptomics, proteomics, metabolomics, and genomics, might lead to the discovery of new biomarkers and the deciphering of complex disease processes [13].

Furthermore, the development of machine learning and artificial intelligence (AI) algorithms presents chances to use large datasets to create decision support systems, therapy algorithms, and prediction models that are customised for each patient's unique CKD profile [14]. Predicting the course of disease, improving treatment plans, and improving patient outcomes are all potential benefits of incorporating AI-driven predictive analytics into clinical practice [15].

Additionally, a new frontier in the therapy of chronic kidney disease (CKD) is the development of targeted medications, such as gene-based therapies, RNA-based interventions, and nanomedicine, which provide precise interventions that target molecular pathways implicated in the pathogenesis of the illness [16]. By focusing on proactive and individualised therapies instead of reactive therapy, research in these areas hopes to change the way that CKD develops naturally [17].

In summary, despite certain obstacles, the field of precision medicine in chronic kidney disease (CKD) has a bright future thanks to technological developments, interdisciplinary teamwork, and an unwavering search for novel approaches that will enhance patient outcomes and change the way CKD care is provided.

REFERENCES

1. Tye, S. C., Denig, P., & Heerspink, H. J. L. (2021). Precision medicine approaches for diabetic kidney disease: Opportunities and challenges. *Nephrology Dialysis Transplantation, 36*(Suppl 2), 3-9. doi:10.1093/ndt/gfab045
2. Koye, D. N., Magliano, D. J., Reid, C. M., Jepson, C., Feldman, H. I., Herman, W. H., & Shaw, J. E. (2018). Risk of progression of nonalbuminuric CKD to end-stage kidney disease in people with diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study. *American Journal of Kidney Diseases, 72*(5), 653-661. doi:10.1053/j.ajkd.2018.02.364
3. Fliser, D., & Wanner, C. (2021). Precision medicine in diabetic nephropathy and chronic kidney disease. *Nephrology Dialysis Transplantation, 36*(Suppl 2), 10-13. doi:10.1093/ndt/gfaa380
4. Provenzano, M., Maritati, F., Abenavoli, C., Bini, C., Corradetti, V., La Manna, G., & Comai, G. (2022). Precision nephrology in patients with diabetes and chronic kidney disease. *International Journal of Molecular Sciences, 23*(10), 5719. doi:10.3390/ijms23105719

5. Gooding, K. M., Lienczewski, C., Papale, M., Koivuviita, N., Maziarz, M., Dutius Andersson, A. M., ... Sourbron, S. (2020). Prognostic imaging biomarkers for diabetic kidney disease (iBEAt): Study protocol. *BMC Nephrology, 21*(1), 242. doi:10.1186/s12882-020-01901-x
6. Iwai, T., Miyazaki, M., Yamada, G., Nakayama, M., Yamamoto, T., Satoh, M., ... Ito, S. (2018). Diabetes mellitus as a cause or comorbidity of chronic kidney disease and its outcomes: The Gonryo study. *Clinical and Experimental Nephrology, 22*(2), 328-336. doi:10.1007/s10157-017-1451-4
7. Pugliese, G., Penno, G., Natali, A., Barutta, F., Di Paolo, S., Reboldi, G., ... De Nicola, L. (2019). Diabetic kidney disease: New clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology. *Nutrition, Metabolism and Cardiovascular Diseases, 29*(11), 1127-1150. doi:10.1016/j.numecd.2019.07.017
8. Duan, S., Chen, J., Wu, L., Nie, G., Sun, L., Zhang, C., ... Yuan, Y. (2020). Assessment of urinary NGAL for differential diagnosis and progression of diabetic kidney disease. *Journal of Diabetes and its Complications, 34*(10), 107665. doi:10.1016/j.jdiacomp.2020.107665
9. Yamanouchi, M., Mori, M., Hoshino, J., Kinowaki, K., Fujii, T., Ohashi, K., ... Ubara, Y. (2019). Retinopathy progression and the risk of end-stage kidney disease: Results from a longitudinal Japanese cohort of 232 patients with type 2 diabetes and biopsy-proven diabetic kidney disease. *BMJ Open Diabetes Research & Care, 7*(1), e000726. doi:10.1136/bmjdrc-2019-000726
10. Alicic, R. Z., Johnson, E. J., & Tuttle, K. R. (2018). Inflammatory mechanisms as new biomarkers and therapeutic targets for diabetic kidney disease. *Advances in Chronic Kidney Diseases, 25*(2), 181-191. doi:10.1053/j.ackd.2017.12.002
11. Kato, M., & Natarajan, R. (2019). Epigenetics and epigenomics in diabetic kidney disease and metabolic memory. *Nature Reviews Nephrology, 15*(6), 327-345. doi:10.1038/s41581-019-0135-6
12. Mauer, M., & Doria, A. (2020). Uric acid and risk of diabetic kidney disease. *Journal of Nephrology, 33*(5), 995-999. doi:10.1007/s40620-020-00796-z
13. Heerspink, H. J. L., Andress, D. L., Bakris, G., Brennan, J. J., Correa-Rotter, R., Dey, J., ... de Zeeuw, D. (2018). Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. *Diabetes, Obesity & Metabolism, 20*(6), 1369-1376. doi:10.1111/dom.13245
14. Kwan, B., Fuhrer, T., Zhang, J., Darshi, M., Van Espen, B., Montemayor, D., ... Natarajan, L. (2020). Metabolomic markers of kidney function decline in patients with diabetes: Evidence from the Chronic Renal Insufficiency Cohort (CRIC) Study. *American Journal of Kidney Diseases, 76*(4), 511-520. doi:10.1053/j.ajkd.2020.01.019
15. Murakoshi, M., Gohda, T., & Suzuki, Y. (2020). Circulating Tumor Necrosis Factor Receptors: A Potential Biomarker for the Progression of Diabetic Kidney Disease. *International Journal of Molecular Sciences, 21*(6), 1957. doi:10.3390/ijms21061957
16. Pugliese, G., Penno, G., Natali, A., Barutta, F., Di Paolo, S., Reboldi, G., ... De Nicola, L. (2020). Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function". *Journal of Nephrology, 33*(1), 9-35. doi:10.1007/s40620-019-00650-x
17. Barutta, F., Bellini, S., Canepa, S., Durazzo, M., & Gruden, G. (2021). Novel biomarkers of diabetic kidney disease: Current status and potential clinical application. *Acta Diabetologica, 58*(7), 819-830. doi:10.1007/s00592-020-01656-9
18. Wang, Y., Zhang, J., Zhang, J., Wu, Y., Zhang, R., Ren, H., ... Liu, F. (2021). Sex Differences in Biopsy-Confirmed Diabetic Kidney Disease. *Frontiers in Endocrinology, 12*, 670674. doi:10.3389/fendo.2021.670674
19. Yang, C., Wang, H., Zhao, X., Matsushita, K., Coresh, J., Zhang, L., ... Zhao, M. H. (2020). CKD in China: Evolving Spectrum and Public Health Implications. *American Journal of Kidney Diseases, 76*(2), 258-264. doi:10.1053/j.ajkd.2019.05.032
20. Ihara, K., Skupien, J., Krolewski, B., Md Dom, Z. I., O'Neil, K., Satake, E., ... Krolewski, A. S. (2021). A profile of multiple circulating tumor necrosis factor receptors associated with early progressive kidney decline in Type 1 Diabetes is similar to profiles in autoimmune disorders. *Kidney International, 99*(3), 725-736. doi:10.1016/j.kint.2020.07.007